By Matthew Holt, Co-Founder, Collaborative Sourcing 3 November 2026
Cinven has agreed to acquire Theramex, the London-based women's health specialty pharmaceutical company, from Carlyle and PAI Partners. It is the third private equity owner since Theramex was carved out of Teva's women's health portfolio in 2018: CVC first, then Carlyle and PAI in 2022, and now Cinven. Financial terms have not been disclosed, though press reports put the value at around €2.6 billion, roughly double the figure reported for the 2022 sale (neither is officially confirmed).
The outgoing owners say EBITDA has more than doubled since 2022, helped by new product launches, acquisitions and in-licensing. They also say they expanded the commercial infrastructure to 17 direct markets and invested in the operating model, supply chain and leadership.
Cinven's own announcement points to the same growth levers: deeper penetration of existing markets, expansion into new ones, and further in-licensing deals, building on a record of launching products and integrating acquired portfolios.
A note before going further: Theramex is not a client of ours, and I have no inside knowledge of its supply chain. Everything below draws on public information. The point is not Theramex itself. It is what a deal like this tells us about where value hides in pharma buyouts.
A Platform Built by Deals Is a Supply Chain Built by Deals
Theramex has grown by carve-out, acquisition and in-licensing. Public announcements include further rights to Zoely from MSD, Duphaston and Femoston from Viatris, a licence for the osteoporosis treatment Eladynos, and a licence-and-supply agreement for Bijuva and Imvexxy outside the US. It now operates in more than 80 countries, up from 57 at the time of the 2022 deal, with products ranging from oral contraceptives to injectable pre-filled pens.
Every one of those moves adds products and, usually, inherited supply arrangements: contract manufacturers chosen by someone else, active ingredient (API) sources the new owner never qualified, packaging specifications designed for another market, and supply terms agreed under a different strategy. Each is manageable alone. Together they form a patchwork that a new owner needs to understand quickly.
Six Places We'd Look First
If we were engaged on an asset like this, these are the questions we would start with:
1. Concentration. Which products, and how much gross profit, sit behind a single manufacturing site or a single API source? Map revenue to product, product to site, and site to inspection history. Our recent piece on Pharmathen shows what one facility can do to nine companies and an investor's equity.
2. Inherited agreements. What do the licence, supply and manufacturing agreements picked up through acquisitions actually say about price mechanisms, minimum volumes, term, technology-transfer rights, and change-of-control or consent clauses? A change of ownership is exactly when those clauses get tested.
3. Cost of goods, component by component. API, excipients (the inactive ingredients), primary and secondary packaging, and contract conversion fees. Price, specification and volume each hide different savings, and acquired products often carry legacy specifications nobody has revisited.
4. Complexity. Eighty-plus countries means pack variants, languages, artwork changes, minimum order quantities and short-dated stock. Complexity shows up as write-offs and tied-up cash, rarely as a clear line in the P&L.
5. Supplier relationships. We segment suppliers on trust and transparency. Those low on both, the critical suppliers nobody really understands, need attention before they become a problem. Those high on both are where win/win partnerships (shared forecasts, joint cost reduction) pay back.
6. Forecasting and service levels. Can the supply side trust the demand signals coming from 17 direct markets plus distributors? Poor forecasts drive both stock-outs and surplus. OTIF (on-time, in-full delivery) is the measure that links supply performance directly to revenue.
What a First 100 Days Could Look Like
Days 1–30: map spend, suppliers, sites and contracts.
Days 30–60: quantify the opportunities and risks, ranked by EBITDA and risk impact.
Days 60–100: start with the changes that need no one's permission, such as renegotiations, specification clean-ups and forecasting routines, and lay out the bigger moves for the plan.
Why This Is About Value, Not Just Cost
Procurement gains largely flow straight through to EBITDA. Better service levels protect revenue. Lower inventory and fewer write-offs release cash. And a supply chain that has been mapped, de-risked and documented is simply easier to sell: whoever buys next will run the same diligence, and the cheapest time to fix findings is early in ownership, not during a sale process.
In our own engagements we have seen an average 8% bottom-line improvement and a 13x average return on investment, moving clients from reactive firefighting to predictable flow. For a mid-sized specialty pharma business, that discipline does not need a large transformation programme. It needs a focused first 100 days.
The Question Worth Asking
Whether you sit on a deal team or run operations in a portfolio company: could you, today, put on one page your ten most important products, the sites that make them, and the sources of their active ingredients, and say which ones you would worry about if a regulator or supplier changed the picture tomorrow? If not, that is a very good first week's work.
Matthew Holt is Co-Founder of Collaborative Sourcing, a procurement consultancy for pharmaceutical, life sciences, and CDMO sectors. His background is in API sourcing and CMO/CDMO management, helping clients and their investors turn supply chain complexity into predictable, value-creating partnerships.
Sources: Cinven, "Cinven to acquire Theramex", 3 November 2026; PE Insights, "PAI Partners and Carlyle agree Theramex sale to Cinven after doubling EBITDA", 3 November 2026; BreakingTheNews report on the reported valuation, 3 November 2026; Carlyle and PAI Partners announcement, March 2022; City A.M., March 2022 (reported 2022 valuation); Theramex company announcements.